Hundreds gathered in NYC to attend the Pink Power Hour, an event aimed to sign up the most people for genetic screening in one hour. Participants got free kits and a live performance by cancer survivor Sheryl Crow. The post Genetic Screening Highlighted During Pink Power Hour appeared first on Inside Precision Medicine.| Inside Precision Medicine
A taste test for influenza is being developed, which produces the flavor of a Mediterranean herb, thyme, when the virus is present. The post Flu Test Detects Virus Through Herby Taste appeared first on Inside Precision Medicine.| Inside Precision Medicine
An existing genetic test for breast cancer could also predict future breast cancer in women with preinvasive lesions, showing early potential for a more personalized treatment approach. The post Polygenic Risk Score Predicts Which Lesions Will Become Breast Cancer appeared first on Inside Precision Medicine.| Inside Precision Medicine
Utilizing point-of-care transcriptomic frameworks, Inflammatix's FDA-approved TriVerity test and Nature Medicine articles offer precise information regarding the host response in intensive care units. The post ICU Care Transformed: Precision Medicine Reaches Sepsis and Critical Illness appeared first on Inside Precision Medicine.| Inside Precision Medicine
The technology combines MRI-based detection with positron emission tomography (PET) and AI to accurately detect bottom-of-sulcus dysplasia (BOSD), a form of focal cortical dysplasia (FCD). The post Epilepsy Caused by Hidden Brain Lesions in Children Uncovered by AI Tool appeared first on Inside Precision Medicine.| Inside Precision Medicine
The authors examined clinical trials, observational data, and consensus of medical experts as they looked to address what is a lingering question in the care of breast cancer patients: can HRT be safely administered to manage debilitating menopause symptoms? The post Experts Urge Rethinking Restrictions on Menopausal MHT After Breast Cancer appeared first on Inside Precision Medicine.| Inside Precision Medicine
Petosemtamab, with pembrolizumab, is in Phase III development for head and neck squamous cel and has two breakthrough therapy designations. The post Genmab to Acquire Merus and Novel Advanced Cancer Prospect for $8 Billion appeared first on Inside Precision Medicine.| Inside Precision Medicine
Sex differences in the diversity of immune cells lining the airways could mean biologic treatments have a different impact on men and women.| Inside Precision Medicine
Defensin-coding genes affect the gut microbiome and protect against metabolic diseases, showing that gut health is not only shaped by diet.| Inside Precision Medicine
Global pharmaceutical company AstraZeneca has partnered with Ghanaian precision medicine company Revna Biosciences to enhance access to advanced lung cancer| The Innovation Spark
PGT-A for women 35 to 42, a group that has a higher risk of producing embryos with chromosomal abnormalities, could improve IVF success.| Inside Precision Medicine
Teal Health has announced the launch of their Teal Wand at-home cervical cancer screening kit and virtual telehealth services in California.| Inside Precision Medicine
The device detects infection via temperature, pH, and inflammation markers such as C-reactive protein (CRP) and interleukin-6 (IL-6).| Inside Precision Medicine
Takeaways from ECOG-ACRIN trials presented at the 2025 American Society of Clinical Oncology Annual Meeting| ECOG-ACRIN Advocacy Blog
AI model outperforms cardiologists in detecting hidden structural heart disease from routine ECGs, advancing early screening.| Inside Precision Medicine
The allogeneic Azer-cel showed impressive response rates in a Phase Ib study with DLBCL patients who had failed autologous CAR T cell therapy treatments.| Inside Precision Medicine
Mapping blood stem cell metabolism reveals choline as a key nutrient to preserve stem cell health and guide precision therapies.| Inside Precision Medicine
Long-term obesity may trigger aging molecular signals in young adults including epigenetic modifications and telomere shortening, researchers have discovered.| Inside Precision Medicine
ISB researchers Drs. Matt Wall, Serdar Turkarslan, Nitin Baliga, and others, along with collaborators, have developed a technology to generate a patient-specific disease-relevance network map to accurately predict risk, personalize therapies, and discover novel drug targets for solid and liquid tumors. The post Baliga Lab researchers and collaborators found that genetic program activity delineates risk, relapse, and therapy responsiveness in multiple myeloma appeared first on Baliga Lab.| Baliga Lab
Here are eight nanotechnology companies that are widening the scope in medicine, that you should know about.| Labiotech.eu
Discover how multivariate analysis is transforming target identification in cancer drug discovery by moving beyond traditional methods.| Labiotech.eu
